Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We report here two cases of ALK-rearranged adenocarcinomas harboring concomitant exon 2 K-RAS mutations (G13D and Q61H).
|
26898615 |
2016 |
Squamous cell carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
APLASIA CUTIS CONGENITA WITH EPIBULBAR DERMOIDS
|
|
0.010 |
GeneticVariation
|
BEFREE |
Both diseases were proposed to represent mosaic disorders, but only very recently whole-genome sequencing has led to the identification of somatic KRAS mutations, p.Leu19Phe and p.Gly13Asp, in affected tissue from two individuals with OES.
|
26970110 |
2016 |
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
BEFREE |
Here, we present a case of JMML with a KRAS G13D mutation.
|
24766281 |
2015 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
|
26623049 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors.
|
26709701 |
2015 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutations in primary tumors were identified in three regions; KARS (G13D) and APC (R876*) in P1-2, TP53 (A161S) in P1-3, and KRAS (G12D), PIK3CA (Q546R), and ERBB4 (T272A) in P1-4.
|
25623536 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression.
|
25359494 |
2015 |
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
Here we report a colon cancer case carrying a novel combination of K-RAS mutations involving codon 13 (Gly to Asp) and codon 19 (Leu to Phe), on separate alleles.
|
25675084 |
2015 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Here we report a colon cancer case carrying a novel combination of K-RAS mutations involving codon 13 (Gly to Asp) and codon 19 (Leu to Phe), on separate alleles.
|
25675084 |
2015 |
Tumour budding
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRas G12V primary tumors had lower apoptosis (7.0 ± 1.2 vs. 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs. 0.6 ± 0.1, P = 0.04), and a higher percentage of C-X-C chemokine receptor type 4 (CXCR4)-overexpressing intravasated tumor emboli (49.8 ± 9.4% vs. 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors.
|
25359494 |
2015 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
|
24558511 |
2014 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Participating laboratories contributed information on KRAS mutation frequencies, including the G13D mutation type, as well as turnaround times for tumor block retrieval and testing.
|
24811330 |
2014 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far.
|
25367198 |
2014 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
23182985 |
2013 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Whereas, the KRAS mutation p.Gly13Asp have been detected only in MSI-H. 43.75 % of the patients harboured combined mutations in KRAS and TP53 genes and the tumor of 71.42 % of them showed TP53 overexpression.
|
24078161 |
2013 |